EP0923528B1 - Oligosaccharide synthesis - Google Patents
Oligosaccharide synthesis Download PDFInfo
- Publication number
- EP0923528B1 EP0923528B1 EP97935368A EP97935368A EP0923528B1 EP 0923528 B1 EP0923528 B1 EP 0923528B1 EP 97935368 A EP97935368 A EP 97935368A EP 97935368 A EP97935368 A EP 97935368A EP 0923528 B1 EP0923528 B1 EP 0923528B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- resin
- linker
- substituted
- support
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C[C@](*)(CC1*=C)OC(COC(C)=O)[C@@]1OC(C)=O Chemical compound C[C@](*)(CC1*=C)OC(COC(C)=O)[C@@]1OC(C)=O 0.000 description 5
- BMJYWTDAFAJETQ-YFHOEESVSA-N CC(C)(CC(/C1=C(\C)/ON)=O)C/C1=[O]/C Chemical compound CC(C)(CC(/C1=C(\C)/ON)=O)C/C1=[O]/C BMJYWTDAFAJETQ-YFHOEESVSA-N 0.000 description 1
- SGLNJXYVJZVQQR-PRTVBDMESA-N NCC(COC1[C@@H]2OC(c3ccccc3)OC1)C2O Chemical compound NCC(COC1[C@@H]2OC(c3ccccc3)OC1)C2O SGLNJXYVJZVQQR-PRTVBDMESA-N 0.000 description 1
- VJUWEOQGLBCSCA-KZBHQWPGSA-N N[C@@H](CC1OCc2ccccc2)OC2[C@@H]1OC(c1ccccc1)OC2 Chemical compound N[C@@H](CC1OCc2ccccc2)OC2[C@@H]1OC(c1ccccc1)OC2 VJUWEOQGLBCSCA-KZBHQWPGSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Definitions
- This invention relates to methods for synthesis of oligosaccharides, and in particular to methods for solid phase or combinatorial synthesis of oligosaccharides.
- the invention provides a novel linker-resin, linker-saccharide, or resin-linker-saccharide complex, which in one embodiment enables a saccharide residue to be linked to a soluble or insoluble polymeric support for use as a basis for solid-phase synthesis of oligosaccharides.
- the complex of the invention enables oligosaccharides to be linked to a solid polymeric support for use as an analytical reagent.
- Oligosaccharides constitute a major class of bioactive polymers, implicated in biochemical processes (Lasky, 1992; Varki, 1993) as diverse as cellular differentiation, hormone-cell recognition and cell-cell adhesion, especially viral-host cell (Gambaryan et al, 1995) and bacteria-host cell attachment (Boren et al , 1993). Involvement of oligosaccharides in diseases such as cancer, cardiovascular disorders, microbial infections, graft rejection and autoimmune disorders has therefore, been strongly suggested. Conjugation of carbohydrates to bioactive peptides has also been demonstrated to stabilise the peptides against degradation, and, in more specific circumstances, to facilitate peptide transport across biological barriers (Lee, 1989; Fisher, 1991; Rodriguez, 1989). Thus the ability to synthesise oligosaccharides in a facile and efficient manner is now becoming an extremely important area within organic chemistry.
- SPPS enables peptide and polypeptide synthesis to be employed as a routine research and synthetic tool, and permits large-scale combinatorial synthesis of peptides for screening of potential pharmaceutical agents.
- Douglas and coworkers described the synthesis of D-mannopentose using a polyethyleneglycol ⁇ -monomethylether co-polymer and a succinoyl or an ⁇ , ⁇ '-dioxyxylyl diether linker (Douglas et al , 1995).
- the reactions were carried out in solution phase, with removal of unused reactants being achieved by precipitation of the oligosaccharide-polymer complex and subsequent washing.
- cleavage of the oligosaccharide-polymer bond was achieved through catalytic hydrogenation, which required exposure of the conjugate to 1 atm of H 2 for 48 h to achieve respectable yields.
- the above examples serve to illustrate that the critical element in solid phase synthesis is the nature of the linker between the solid support and the initial synthon.
- the linker must display excellent stability to the conditions of coupling and deprotection, yet in the case of solid phase oligosaccharide synthesis, it should also be rapidly and efficiently cleaved to allow monitoring of the progress of individual coupling reactions.
- the cleavage should ideally be achieved by the use of a relatively innocuous chemical reagent.
- a hydrazine-labile primary amino-protecting group N -1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde), has been reported for protection of lysine side chains during SPPS (Bycroft et al , 1993).
- This group was modified for use as a carboxy-protecting group in SPPS when the 2-(3-methylbutyryl)dimedone analogue of 2-acetyldimedone was condensed with 4-aminobenzylalcohol to afford 4-[ N -[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino]benzyl ester (ODmab)(Chan et al , 1995).
- the two protecting groups were reported to be stable to the deprotecting conditions widely used in SPPS, ie . trifluoroacetic acid (TFA) or 20% piperidine in dimethyl formamide (DMF).
- TFA trifluoroacetic acid
- DMF dimethyl formamide
- ethyl ester, 4-(N-(1-(4,4-dimethyl-2, 6-dioxocyclohexylidene)ethyl)amino)benzyl ester (ODab) showed small but significant instability to 20% piperidine-DMF.
- Dde and ODmab are linked to groups on amino acids, rather than directly to the solid-phase support. Their use in solid-phase oligosaccharide synthesis has not been suggested.
- Bannwarth et al have independently developed a different solid phase linker around the Dde protecting group, which they have utilised for the immobilisation of amino acids and primary amines for combinatorial library synthesis (Bannwarth et al , 1996). However, the synthesis of this linker is both protracted and inefficient, and the linker only displays a limited stability to secondary bases such as piperidine. There has been no suggestion that this linker could be used for oligosaccharide synthesis. The linkers we have developed demonstrate a far greater stability than those of Bannwarth et al.
- the invention provides a support for solid-phase synthesis of oligosaccharides, said support comprising:
- Other possible covalent linking groups will be known to those skilled in the art.
- both R 1 and R 2 are methyl.
- R' is an oligosaccharide-O-CH 2 -(C 6 H 4 )-NH, monosaccharide-O-CH 2 -(C 6 H 4 )-NH, amino-oligosaccharide-CO 2 CH 2 - (C 6 H 4 )NH, or amino-monosaccharide-CO 2 CH 2 -(C 6 H 4 )-NH group.
- the 2-substituted-1,3-dioxocycloalkane linker is functionalised Dde, Ddh or ODmab.
- the support comprises a resin, a linker and a monosaccharide, an oligosaccharide, an aminosaccharide or an amino-oligosaccharide.
- the invention provides a support for solid-phase synthesis comprising a resin and a support group, wherein the support is a 2-substituted-1,3-dioxocycloalkane of general formula II: in which
- the invention provides a support-saccharide complex, comprising a support group of general formula II as defined above and a saccharide group as defined above for R'.
- the invention provides a linker compound carrying functional groups suitable to attach a primary amine to a resin via covalent bonds which are stable to conditions of oligosaccharide synthesis and cleavage, said compound having general formula III in which
- the linker compound is 6-hydroxyl-6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoic acid or an ester thereof.
- the ester is a benzyl, methyl, or t-butyl ester.
- substituted in the definitions of substituents within this specification means that the substituent is itself substituted with a group which does not change the general chemical characteristics of the substituent.
- Preferred such further substituents are halogen, nitro, amino, hydroxyl, and thiol; preferred halogens are chlorine and iodine.
- substituents of similar size and charge characteristics which could be used as alternatives in a given situation.
- a compound is regarded as "stable to conditions of oligosaccharide synthesis and cleavage" if there is less than 10% loss of the compound after exposure at room temperature to ammonia, hydrazine or a primary amino compound in water or DMF.
- the person skilled in the art will readily be able to determine whether the stability of a particular compound is adequate for it to be useful for the purposes of the invention, using conditions appropriate for his or her particular needs.
- the linker compound of the invention may be synthesized on the resin, or may be synthesized in solution.
- kits useful in solid phase synthesis or combinatorial synthesis of oligosaccharides comprising either
- the resin may be any resin which swells in water and/or in an organic solvent, and which comprises one of the following substituents: halogen, hydroxy, carboxyl, SH, NH 2 , formyl, SO 2 NH 2 , or NHNH 2 , for example methylbenzhydrylamine (MBHA) resin, amino or carboxy tentagel resins, 4-sulphamylbenzyl AM resin.
- Suitable resins will be known to those skilled in the art.
- the invention also provides a method of solid-phase synthesis of oligosaccharides, comprising the step of sequentially linking mono- or oligosaccharide groups to a support as described above.
- the mono- or oligosaccharide building blocks may be as described above.
- This method is particularly useful for combinatorial synthetic application.
- the linker compound may be synthesised in solution or directly on the resin in a stepwise manner prior to the coupling of the initial sugar group, or the linker-initial sugar conjugate may be synthesised in solution phase and subsequently coupled to the solid support, with subsequent sugars being sequentially attached.
- the second and all subsequent sugar groups are coupled to the oligosaccharide chain-resin conjugate after the last sugar in the oligosaccharide chain is partially deprotected.
- the invention accordingly provides a method of synthesis of a support group according to general formula I as defined above, comprising the step of C-acylation of a 2-substituted 1,3-dioxocyclohexane compound with a dicarboxylic acid.
- the dicarboxylic acid is mono-protected by ester formation. More preferably the reaction is activated with carbodiimide and catalysed by N,N'-dimethylaminopyridine.
- the product of the reaction may optionally be reacted with 4-aminobenzyl alcohol, to form the 4-aminobenzyl derivative.
- the invention also provides a method of synthesis of a resin-linker support, comprising the step of swelling a resin in a suitable solvent, treating the swollen resin with a dicarboxylic acid, and reacting the thus-produced product with a 2-substituted 1,3-dioxocycloalkane compound.
- a 2-substituted 1,3-dioxocycloalkane compound is 5,5-dimethyl-1,3-cyclohexanedione.
- the dicarboxylic acid is adipic acid.
- the first sugars attached to the resin-linker unit may be unprotected, partially protected or fully protected glycosides, aminoglycosides, or ether- or amino-linked sugars, where the coupling takes place through a non-glycosidic position.
- the building block mono- or oligosaccharide-donors may be any activated sugar, including but not limited to orthoesters, thioorthoesters, cyanoalkylidene derivatives, 1- O -acyl sugars, amino sugars, acetimidates, trichloroacetimidates, thioglycosides, aminoglycosides, amino-oligosaccharides, glycosylamines of oligosaccharides, glycosyl thiocyanates, pentenyl glycosides, pentenoylglycosides, isoprenyl glycosides, glycals, tetramethylphosphoro diamidates, sugar diazirines, selenoglycosides, phosphorodithioates, glycosyldialkylphosphites, glycosylsulphoxides and glycosylfluorides.
- activated sugar including but not limited to orthoesters, thio
- the first sugar coupled to the resin is an aminosugar, an aminoglycoside, or an amino-oligosaccharide or a glycosyl amine of an oligosaccharide.
- partial sugar deprotection is achieved by using acyl-type, trityl, benzyl-type, acetal-type, or various silyl and/or photolabile protecting groups in addition to permanent protecting groups.
- This permits the synthesis of branched oligosaccharides by using two orthogonal hydroxy-protecting groups on a single sugar donor.
- the synthesised oiigosaccharide can be cleaved from the resin using ammonia, hydrazine or a primary amine, such as butylamine or cyclohexylamine.
- ammonia or a suitable primary amine in an organic solvent is preferably employed.
- hydrazides hydrazine in water or in an organic solvent is preferably employed.
- oligosaccharides ammonia in water or in an organic solvent is preferably employed, followed by acidification.
- oligosaccharide can be retained on the resin for use as an analytical or preparative reagent, for example in affinity chromatography or for bulk-scale affinity separation.
- the invention is based upon the immobilisation of a Dde-, Ddh or ODmab-based linker to a polymer support in order to tether any saccharide or oligosaccharide group.
- This has been illustrated by the coupling of N - and O -glycosides to the linkers, which have been used for oligosaccharide synthesis following coupling to the resin.
- the nature of these linkers is such that as well as the potential to immobilise any type of sugar, any sugar donor can be subsequently used for oligosaccharide synthesis, thereby allowing rapid and efficient coupling procedures.
- Suitable sugar donors include, but are not limited to orthoesters, thioorthoesters, cyanoalkylidene derivatives, 1- O -acyl sugars, acetimidates, trichloroacetimidates, thioglycosides, glycosyl thiocyanates, pentenyl glycosides, pentenoylglycosides, isoprenyl glycosides, glycals, tetramethylphosphoro diamidates, sugar diazirines, selenoglycosides, phosphorodithioates, glycosyldialkylphosphites, glycosylsulphoxides and glycosylfluorides.
- the stability of the linkers means that orthogonal hydroxy-protecting groups can be employed in sugar protection.
- These protecting groups include, but are not limited to, acyl-type, trityl, benzyl type, acetal type or various silyl and photolabile protecting groups.
- linker synthesis also means that any functionalised resin may be used to immobilise the linker, eg. MBHA resin, amino or carboxy tentagel resins, 4-sulfamylbenzoyl AM resin etc.
- any functionalised resin may be used to immobilise the linker, eg. MBHA resin, amino or carboxy tentagel resins, 4-sulfamylbenzoyl AM resin etc.
- C-Acylation of dimedone with, for example, a mono-protected di-carboxylic acid is readily achieved via a carbodiimide activated, DMAP catalysed condensation in dry DCM.
- Removal of the ester protection and coupling of the first amino sugar residue generates a sugar-linker conjugate which can be coupled readily to an amino-functionalised resin support via a carbodiimide-mediated condensation.
- This reaction can be monitored using conventional amine tests such as TNBS or ninhydrin, to ensure quantitative acylation.
- the linker can be synthesised directly on the resin, followed by introduction of the first sugar residue on to the linker-resin conjugate. Both methods are illustrated in Figure 3.
- the second sugar residue is coupled using any of the sugar donors referred to above, as illustrated in Figure 8.
- a portion of the resin is readily cleaved using either ammonia, hydrazine or a primary amine, as shown in Figure 5, and the cleavage mixture is analysed by TLC to monitor the reaction progress. Completion of the reaction is indicated by the disappearance of the monosaccharide.
- the sequential deprotection and coupling of the following sugar residues is continued until the desired oligosaccharide is complete, as illustrated in Figure 1.
- the protecting groups are then removed, and the oligosaccharide is cleaved from the resin support using either ammonia, hydrazine, or a primary amine, in a suitable solvent.
- the resin-linker system of the invention is ideal for the synthesis of combinatorial oligosaccharide libraries , as shown in Figure 2, and for the immobilisation of mono- or oligosaccharides, as shown in Figure 7.
- Ethyl 4,6-O-benzylidene-1-thio- ⁇ -D-galactopyranoside (6.90 g, 22.11 mmol) in 60 ml DMF was added dropwise at 0°C to a suspension of sodium hydride 60% (2.65 g, 66.34 mmol) in 60 ml DMF. The mixture was stirred at room temperature for 1 hour, then benzyl bromide (11.34 g, 66.34 mmol) was added dropwise at 0°C. The mixture was stirred at room temperature overnight. The mixture was evaporated, and xylene (2x50 ml) was distilled from the residue.
- 1,2,3,4,6-penta-O-acetyl-galactopyranose (1.17 g, 3 mmol) was dissolved in dry CH 2 Cl 2 (15 ml), then trimethylsilyl azide (416 mg, 3.6 mmol) and SnCl 4 (0.18 ml) were added under nitrogen. The mixture was stirred at room temperature for 24 hours. The reaction mixture was subsequently diluted with CH 2 Cl 2 (40 ml), dried over MgSO 4 and evaporated.
- reaction mixture was evaporated and purified by chromatography using CHCl 3 /EtOH 10:0.3 v/v to give 2,3,6-tri-O-benzyl- ⁇ -D-galactopyranosyl amine (2.66 g, 94%); R f 0.38 (CHCl 3 /EtOH 10:0.3 v/v); FAB MS C 27 H 31 NO 5 (449.33) m/z (%) 472 [M+Na] + (75), 450 [M+H] + (100).
- N-(Benzyl 6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoate-6-yl) 2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl amine (1.27 g, 1.84 mmol) was hydrogenated over Pd/C (10%) (200 mg) in MeOH (20 ml) at room temperature for 10 hours.
- reaction mixture was evaporated and chromatographed using CHCl 3 /MeOH 10:0.5 v/v to give N-(6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoic acid-6-yl) 2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl amine(410 mg, 92%).
- Reaction 21 was repeated with the difference that 2,3,6-tri-O-benzyl- ⁇ -D-galactopyranosyl amine was used instead of 2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl amine, and afforded N-(6-(4,4-dimethyl-2,6-dioxocyclo-hexylidene)-hexanoic acid-6-yl) 2,3,6-tri-O-benzyl- ⁇ -D-galactopyranosyl amine (299 mg, 90%).
- Reaction 21 was repeated with the difference that 4-aminobenzyl alcohol was used instead of 2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl amine, and afforded N-(6-4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoic acid-6-yl) 4-aminobenzyl alcohol (259 mg, 94%).
- N-(t-Butyl 6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoate-6-yl) 4-aminobenzyl trichloroacetimidate 400 mg, 0.70 mmol was added at 20°C under nitrogen to a solution of Benzyl 2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy- ⁇ -D-glucopyranoside (155 mg, 0.35 mmol) in CH 2 Cl 2 (6 ml). Trifluoromethanesulphonic acid in ether (0.1 M, 0.06 ml) was added and the mixture was stirred for 30 min at 20°C.
- MBHA resin (Subst. ratio: 0.42 mmol/g) (200 mg) bearing a total amine functionality of 0.084 mmol was swollen in DMF for 20 min. The resin was then washed with fresh DMF and N-(6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoic acid-6-yl) 2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl amine (200 mg, 4 equiv.) and N,N'-diisopropylcarbodiimide (53 ⁇ l,4 equiv.) were added in DMF (5 ml) and the resin gently agitated for 30 min.
- the TNBS test was faintly positive so using the above conditions, a double coupling was performed, this time producing a negative TNBS test result.
- the resin was washed with DMF, methanol and finally ether. The resin was then allowed to dry in vacuum over KOH overnight.
- MBHA resin (100 mg) bearing a total amine functionality of 0.042 mmol was swelled in DMF for 20 min. The resin was then washed with fresh DMF and N-(6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoic acid-6-yl) 4-aminobenzyl alcohol (63 mg, 4 equiv.) and 1-isobutyloxycarbonyl-2-isobutyloxy-1,2-dihydroquinoline (EEDQ) (51 mg, 4 equiv.) were added in DMF (5 ml) and the resin gently agitated for 24 h. The TNBS test was faintly positive so using the above conditions, a double coupling was performed, this time producing a negative TNBS test result. The resin was washed with DMF (5x10 ml).
- MBHA resin (1.0 g) bearing a total amine functionality of 0.42 mmol was swelled in DMF for 20 min. The resin was then treated with a mixture of adipic acid (1.41 g, 10 mmol) and N,N'-diisopropylcarbodiimide in CH 2 Cl 2 (10 ml) for 60 min. A second coupling was performed in DMF to get a negative ninhydrin test. The resin was washed with DMF (5x10 ml).
- the resin from Example 38 was gently agitated with sodium methoxide (200 mg, 3.70 mmol) in abs. MeOH (5 ml) at room temperature for 1 h. The resin was washed with abs. MeOH (5x10 ml), DMF(5x10 ml), ether (5x10 ml) and dried under high vacuum for 1 h, giving the resin-bonded unprotected ⁇ -D-glucopyranosyl amine. A sample of resin (5 mg) was cleaved by NH 3 /MeOH (Example 41), and the resulting product was analyzed by TLC and mass spectometry, proving the quantitative deprotection.
- the resin from Example 44 was treated with NH 3 /MeOH (10 ml) for 5 min. The resin was filtered off, and the filtrate was evaporated giving a mixture of disaccharides, trisaccharides, and tetrasaccharides.
- the resin from Example 46 was gently agitated with sodium methoxide (200 mg, 3.70 mmol) in abs. MeOH (5 ml) at room temperature for 1 h. The resin was washed with abs. MeOH (5x10 ml), DMF(5x10 ml), ether (5x10 ml) and dried under high vacuum for 1 h, giving the resin bonded partially unprotected disaccharide.
- a sample of resin (5 mg) was cleaved by NH 3 /MeOH (Example 41) and the resulting product was analyzed by TLC and mass spectometry, proving the quantitative deprotection.
- Example 29 The resin from Example 29 was treated with NH 3 /MeOH (5 ml) overnight. The resin was filtered off, and the filtrate was evaporated giving 4-aminobenzyl ⁇ -D-glucopyranoside. R f 0.55 (CHCl 3 /MeOH/H 2 O 10:4:0.5 v/v/v); FAB MS C 13 H 19 NO 5 (269.28) m/z (%) 402 [M+Cs] + (25), 292 [M+Na] + (50), 270 [M+H] + (18).
- the resin from Example 37 was reacted with O-[O-(2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl(1 ⁇ 4))-2,3,6-tri-O-acetyl- ⁇ -D-glucopyranosyl (1 ⁇ 4)]-2,3,6-tri-O-acetyl- ⁇ -D-glucopyranosyl amine (1.80 g, 2.00 mmol) in DMF (5 ml) at room temperature for 2 days. The resin was washed with DMF (5x10 ml).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
said support having general formula I: in which
- R1 and R2 may be the same or different, and is each hydrogen or C1-4 alkyl;
- R' is an amino sugar, a glycosylamine, or a glycosylamine of an oligosaccharide; a mono or oligosaccharide coupled through an alkyl-, substituted alkyl-, aryl-, substituted aryl-, cycloalkyl-, or substituted cycloalkyl-amino group; or a mono or oligosaccharide coupled through a carboxyalkyl-, substituted carboxyalkyl-, carboxyaryl-, substituted carboxyaryl-, carboxycycloalkyl-, or substituted carboxycycloalkyl-amino group; and
- R" is an alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl spacer group which is directly coupled to the resin support, or which may optionally be coupled to the resin support via a suitable covalent linkage, which is stable to conditions of oligosaccharide synthesis and cleavage.
- Bn
- Benzyl
- Bu
- Butyl
- DCM
- Dichloromethane
- Dde
- N-1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)ethyl
- Ddh-OH
- 6-Hydroxy-6-(4,4-dimethyl-2,6-dioxocyclohexylidene)hexanoic acid
- DMAP
- N,N'-Dimethyl aminopyridine
- DMF
- N,N'-Dimethylformamide
- DMTST
- Dimethyl(methylthio)sulphonium trifluoromethanesulphonate
- EEDQ
- 1-Isobutyloxycarbonyl-2-isobutyloxy-1,2-dihydroquinoline
- EtOAc
- Ethyl acetate
- EtOH
- Ethanol
- FAB-MS
- Fast atom bombardment mass spectrometry
- HRMS
- High resolution mass spectrometry
- MBHA
- Methyl benzyhydrylamine resin
- Me
- Methyl
- MeOH
- Methanol
- NMR
- Nuclear magnetic resonance
- ODmab
- 4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl] -amino}benzyl alcohol.
- PEG
- Polyethylene glycol
- tBu
- tetra-butyl
- TFA
- Trifluoroacetic acid
- THF
- Tetrahydrofuran
- TLC
- Thin-layer chromatography
- TNBS
- 2,4,6-Trinitrobenzene sulphonic acid
Rf 0.43 (hexane/EtOAc 1:1); FAB MS C16H24O9S (392.3) m/z (%) 415 [M+Na]+ (100), 393 [M+H]+ (20), 331 (56).
Rf 0.64 (CHCl3/ethanol 10:3).
Rf 0.51 hexane/EtOAc 1:1 v/v); 1H NMR (CDCl3) δ 7.55-7.25 (m, 15H, 15 Ar-H), 5.47 (s, 1H, CHAr), 4.88-4.75 (4d, 4H, 2 CH2Ar), 4.44 (d, 1H, H-1, J1,2=10.89 Hz), 4.30 (dd, 1H, H-6'), 4.16 (d, 1H, H-4), (3.97 (dd, 1H, H-3), 3.88 (t, 1H, H-2), 3.60 (dd, 1H, H-6), 3.35 (d, 1H, H-5), 2.90-2.40 (m, 2H, CH2S), 1.33 (t, 3H, Me); FAB MS C29H32O5S, (492.40) m/z (%) 515 [M+Na]+ (100), 493 [M+H]+ (41), 431 (53).
Rf 0.43 (1,2-dichloroethane/EtOAc 10:0.5 v/v); 1H NMR (CDCl3) δ 7.40-7.26 (m, 15H, 15 Ar-H), 4.88, 4.76,4.73, 4.71 (4d, 4H, 2 CH2Ar), 4.57 (s, 2H, CH2Ar), 4.42 (d.1H, H-1, J1,2=9.64 Hz), 4.10 (m, 1H, H-4), (3.76 (dd, 1H, H-3), 3.67 (t, 1H, H-2), 3.55 (m, 2H, H-6), 2.75 (m, 2H, CH2S), 2.50 (bs, 1H, OH), 1.31 (t, 3H, CH3); FAB MS C29H34O5S (494.61) m/z (%) 627 [M+Cs]+ (70), 517 [M+Na]+ (30), 495 [M+H]+ (12).
1H NMR (CDCl3) δ 7.40-7.25 (m, 15H, 15 Ar-H), 4.80-4.50 (m, 6H, 3 CH2Ar), 4.45 (d, 1H, H-1, J1,2=9.53 Hz), 2.73 (m, 2H, CH2S), 1.30 (t, 3H, CH3); FAB MS C31H35BrO6S (615.56) m/z (%) 638 [M+Na]+ (15), 616 [M+H]+ (32), 509 (80), 463 (21), 419 (18).
Rf 0.74 (hexane/EtOAc 8:7 v/v); 1H NMR (CDCl3) δ 5.41 (d, 1H, H-4), 5.17 (t, 1H, H-2), 5.04 (dd, 1H, H-3), 4.60 (d,1H, H-1, J1,2=10.09 Hz), 4.19 (m, 2H, H-6), 4.00 (m, 1H, H-5), 2.15-1.98 (4s, 12H, 4 OAc); FAB MS C14H19N3O9 (373.32) m/z (%) 396 [M+Na]+ (100), 374 [M+H]+ (35), 331 (23).
Rf 0.64 (CHCl3/ethanol 10:1.5).
Rf 0.42 (1,2-dichloroethane/EtOAc 10:0.4 v/v); 1H NMR (CDCl3) δ 7.40 (m, 15H, 15 Ar-H), 4.90-4.55 (m, 6H, 3 CH2Ar), 4.06 (m, 1H, H-4), (3.82-3.70 (m, 3H, H-3, H-2, H-5), 3.65 (dd, 1H, H-6'), 3.60 (d, 1H, H-1, J1,2= 8.64 Hz), 3.51 (dd, 1-H, H-6); FAB MS C27H29N3O5 (475.40) m/z (%) 608 [M+Cs]+ (10), 498 [M+Na]+ (65), 476 [M+H]+ (25), 433 (75), 341 (20).
Rf 0.38 (CHCl3/EtOH 10:0.3 v/v); FAB MS C27H31NO5 (449.33) m/z (%) 472 [M+Na]+ (75), 450 [M+H]+ (100).
Rf 0.32 (hexane/EtOAc 1:1 v/v); 1H NMR (CDCl3) δ 7.37-7.26 (m, 5H, 5 Ar-H), 5.40-5.00 (m, 7H, 7 sugar protons), 3.10, 2.85 (2t, 4H, 2 CH2), 2.38 (2s, 4H,
Rf 0.38 (CHCl3/MeOH 10:0.5 v/v); 1H NMR (CDCl3) δ 5.40-5.00 (m, 7H, 7 sugar protons), 3.15, 2.86 (2t, 4H, 2 CH2), 2.45 (2s, 4H,
Rf 0.28 (hexane/EtOAc 1:1 v/v) ;FAB MS C29H41NO13 (611.45) m/z (%) 624 [M+Na]+ (100), 612 [M+H]+ (34).
Rf 0.35 (hexane/EtOAc 1:1 v/v); FAB MS C32H47NO13 (653.37) m/z (%) 676 [M+Na]+ (80), 677 [M+H]+ (100).
1H NMR (CDCl3) δ 18.10 (s. 1H, OH), 7.30 (s, 5H, 5Ar-H), 5.06 (s, 2H, CH2Ar), 3.00 (t, 2H, CH2), 2.47 (s, 2H, Dde CH2), 2.35 (t, 2H, CH2CO2), 2.29 (s, 2H, Dde CH2), 1.65 (m, 4H, 2 CH2), 1.01 (s, 6H, 2 CH3); FAB MS C21H26O5 (358.18) m/z (%) 359 [M+H]+ (100), 267 (40); HRMS (FAB) Found: m/z 359.1858 Calcd for C21H27O5: (M+H), 359.1850.
Rf 0.35 (hexane/EtOAc 2:1 v/v); , FAB MS C14H20O5 (268.12) m/z (%) 313 [M+2Na]+ (34), 291 [M+Na]+ (100), 269 [M+H]+ (16).
Rf 0.32 (EtOAc/hexane 1:2 v/v) FAB MS C15H22O5 (282.22) m/z (%) 305 [M+H]+ (100), 283 [M+H]+ (66).
Rf 0.36 (EtOAc/hexane 1:2 v/v) FAB MS C18H28O5 (324.41) m/z (%) 347 [M+H]+ (100), 325 [M+H]+ (43), 267 (80).
Rf 0.34 (CHCl3/MeOH 10:0.1 v/v) FAB MS C37H43NO7 (613.41) m/z (%) 649 [M+2Na]+(34), 626 [M+Na]+ (100), 614 [M+H]+ (65).
Rf 0.40 (EtOAc/hexane/acetic acid 2:1:0.1 v/v/v); FAB MS C21H27NO5 (373.43) m/z (%) 418 [M+2Na]+ (24), 396 [M+Na]+ (100), 374 [M+H]+ (35).
Rf 0.52 (CHCl3/MeOH 9:1 v/v) FAB MS C25H35NO5 (429.53) m/z (%) 452 [M+Na]+ (100), 430 [M+H]+ (32), 372 (64).
Rf 0.41 (EtOAc/hexane 1:1 v/v); FAB MS C27H35Cl3N2O5 (573.94) m/z (%) 595 [M+Na]+ (100), 753 [M+H]+ (40), 515 (39), 430 (54).
R; 0.37 (EtOAc/hexane 2:1 v/v); FAB MS C49H62N2O11(855.01) m/z (%) 877 [M+Na]+ (100), 855 [M+H]+ (35), 797 (73).
Rf 0.47 (hexane/EtOAc 1:1 v/v); FAB MS C42H51NO14 (793.83) m/z (%) 816 [M+Na]+ (100), 794 [M+H]+ (25), 702 (66).
Rf 0.34 (CHCl3/MeOH 10:0.1 v/v) FAB MS C37H43NO7 (613.41) m/z (%) 649 [M+2Na]+(34), 626 [M+Na]+ (100), 614 [M+H]+ (65).
FAB MS disaccharides C33H41NO9 (595.66), trisaccharides C60H69NO13 (1012.16), tetrasaccharides C87H97NO17 (1429.66) (m/z (%) 618 [Mdi+Na]+ (41), 596 [Mdi+H]+ (57), 1034 [Mtri+Na]+ (56), 1012 [Mtri+H]+ (100), 1450 [Mtetra+Na]+ (8) 1428 [Mtetra+H]+ (10).
Rf 0.55 (CHCl3/MeOH/H2O 10:4:0.5 v/v/v); FAB MS C13H19NO5 (269.28) m/z (%) 402 [M+Cs]+ (25), 292 [M+Na]+ (50), 270 [M+H]+ (18).
Tetrahedron Lett., 1996 37 5007.
Bioorganic and Med. Chem. Lett., 1996 6 1525.
Science, 1993 262 1892.
J. Chem. Soc., Chem. Commun., 1993 778.
J. Chem. Soc., Chem. Commun., 1995 2209.
J. Am. Chem. Soc., 1995, 117 2116.
J. Med. Chem., 1991 34 3140.
J. Am. Chem. Soc., 1971 93 492.
J. Am. Chem. Soc., 1972 94 604.
FEBS Lett., 1995 366 57.
J. Am. Chem. Soc., 1971 (c) 2690.
J. Chem. Soc., Perkin Trans. 1, 1973 1 2441.
Science, 1992 258 964.
in Carbohydrate Recognition in Cellular Function (G Block and S. Harnett, Eds.), John Wiley & Sons, 1989 80.
J. Am. Chem. Soc., 1963 85 2149.
Tetrahedron Lett., 1996, 37 3989.
J. Am. Chem. Soc., 1995 117 5712.
Science, 1995 269 202.
Neurosci. Lett., 1989 101 89.
Glycobiology, 1993 3 97.
J. Am. Chem. Soc., 1994 116 6953.
Claims (26)
- A support for solid-phase synthesis of oligosaccharides, said support comprisingwherein the linker is a 2-substituted-1,3-dioxocycloalkane compound, anda) a resin,b) a linker covalently attached to the resin, andc) one or more saccharide groups covalently attached to the resin via the linker,
said support having general formula I in whichR1 and R2 may be the same or different, and is each hydrogen or C1-4 alkyl; preferably both R1 and R2 are methyl;R' is an amino sugar, a glycosylamine, or a glycosylamine of an oligosaccharide; a mono or oligosaccharide coupled through an alkyl-, substituted alkyl-, aryl-, substituted aryl-, cycloalkyl-, or substituted cycloalkyl-amino group; or a mono or oligosaccharide coupled through a carboxyalkyl-substituted carboxyalkyl-, carboxyaryl-, substituted carboxyaryl-, carboxycycloalkyl-, or substituted carboxycycloalkyl-amino group, andR" is an alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl spacer group which is directly coupled to the resin support, or which may optionally be coupled to the resin support via a covalent linkage which is stable to conditions of oligosaccharide synthesis and cleavage. - A support according to Claim 1, in which both R1 and R2 are methyl.
- A support according to Claim 1 or Claim 2, in which R' is an oligosaccharide-O-CH2-(C6H4)-NH, monosaccharide-O-CH2-(C6H4)-NH, amino-oligosaccharide-CO2CH2-(C6H4)NH, or amino-monosaccharide-CO2CH2-(C6H4)-NH group.
- A support according to any one of Claims 1 to 3, in which the covalent linkage to the resin is provided by a -CONH-, -O-, -S-, -COO-, -CH=N-, -NHCONH-, -NHCSNH, or -NHNH- grouping.
- A support according to any one of Claims 1 to 4, in which the linker is functionalised Dde, Ddh or ODMab.
- A support according to any one of Claims 1 to 5, comprising a resin, a linker and a monosaccharide, an oligosaccharide, an aminosaccharide or an amino-oligosaccharide.
- A support for solid-phase synthesis comprising a resin and a linker group, wherein the support is a 2-substituted-1,3-dioxocycloalkane of general formula II: in whichX is OH;R1 and R2 may be the same or different, and is each hydrogen or C1-4 alkyl; andR" is an alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl spacer group which is directly coupled to the resin support, or which may optionally be coupled to the resin support via a covalent linkage which is stable to conditions of oligosaccharide synthesis and cleavage.
- A support according to Claim 7, in which R1 and R2 are both methyl
- A support according to Claim 7 or Claim 8, in which the covalent linkage to the resin is provided by a -CONH-, -O-, -S-, -COO-, -CH=N-, -NHCONH-, -NHCSNH, or -NHNH- grouping.
- A linker-saccharide complex in which the linker group is as defined in Claim 1 or Claim 2 and the saccharide is as defined in Claim 1 or Claim 6.
- A compound carrying functional groups suitable to attach a primary amine to a resin via covalent bonds which are stable to conditions of oligosaccharide synthesis and cleavage, said compound having general formula III in whichX is OH,R1 and R2 may be the same or different, and is each hydrogen or C1-4 alkyl, andR" is an alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl spacer group, which carries a functionality capable of reacting with a functionalised resin.
- A compound according to Claim 11, in which both R1 and R2 are methyl.
- A compound according to Claim 11 or Claim 12, in which the functionality on R" is a carboxyl group.
- A compound according to Claim 11, which is 6-hydroxy-6-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexanoic acid or an ester thereof.
- A compound according to Claim 14, in which the ester is a benzyl, methyl or t-butyl ester.
- A support according to any one of Claims 1 to 6, in which the linker is a compound according to any one of Claims 11 to 15.
- A support according to any one of Claims 7 to 9, in which the linker is a compound according to any one of Claims 11 to 15.
- A linker-saccharide complex according to Claim 10, in which the linker is a compound according to any one of Claims 11 to 15.
- A kit for solid phase synthesis or combinatorial synthesis of oligosaccharides, comprising:and optionally also comprising one or more protecting agents, deprotecting agents, and/or solvents suitable for solid phase or combinatorial synthesis.a) a resin-linker-saccharide support according to any one of Claims 1 to 5 or 16,b) a linker-saccharide complex according to Claims 10 or 17, orc) a resin-linker support according to any one of Claims 7 to 17,
- A method of solid-phase synthesis of oligosaccharides, comprising the step of sequentially linking mono- or oligosaccharide groups to a support as defined in any one of Claims 1 to 9 or 16.
- A method of synthesis of a support according to general formula I as defined in Claim 1, comprising the step of C-acylation of a 2-substituted 1,3-dioxocyclohexane compound with a dicarboxylic acid, and
optionally reacting the product of the C-acylation reaction with 4-aminobenzyl alcohol, to form the 4-aminobenzyl derivative. - A method according to Claim 21, in which the dicarboxylic acid is mono-protected by ester formation.
- A method according to Claim 21 or Claim 22, in which the C-acylation reaction is activated with carbodiimide and catalysed by N,N'-dimethylaminopyridine.
- A method of synthesis of a resin-linker support according to any one of Claims 7 to 9, comprising the step of swelling a resin in a suitable solvent, treating the swollen resin with a dicarboxylic acid, and reacting the thus-produced product with a 2-substituted 1,3-dioxocycloalkane compound.
- A method according to any one of Claims 21 to 24, in which the 2-substituted 1,3-dioxocycloalkane compound is 5,5-dimethyl-1,3-cyclohexanedione.
- A method according to any one of Claims 21 to 25, in which the dicarboxylic acid is adipic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO1905A AUPO190596A0 (en) | 1996-08-26 | 1996-08-26 | Oligosaccharide synthesis |
| AUPO190596 | 1996-08-26 | ||
| PCT/AU1997/000544 WO1998008799A1 (en) | 1996-08-26 | 1997-08-26 | Oligosaccharide synthesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP0923528A1 EP0923528A1 (en) | 1999-06-23 |
| EP0923528A4 EP0923528A4 (en) | 2000-07-19 |
| EP0923528B1 true EP0923528B1 (en) | 2002-11-06 |
Family
ID=3796218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97935368A Expired - Lifetime EP0923528B1 (en) | 1996-08-26 | 1997-08-26 | Oligosaccharide synthesis |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6573337B1 (en) |
| EP (1) | EP0923528B1 (en) |
| JP (1) | JP2001501174A (en) |
| CN (1) | CN1121375C (en) |
| AT (1) | ATE227258T1 (en) |
| AU (1) | AUPO190596A0 (en) |
| CA (1) | CA2264390A1 (en) |
| DE (2) | DE69716931T2 (en) |
| DK (1) | DK0923528T3 (en) |
| ES (1) | ES2150890T3 (en) |
| HU (1) | HUP0000069A3 (en) |
| WO (1) | WO1998008799A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO190596A0 (en) * | 1996-08-26 | 1996-09-19 | Alchemia Pty Ltd | Oligosaccharide synthesis |
| AUPO536797A0 (en) | 1997-02-28 | 1997-03-20 | Alchemia Pty Ltd | Protected aminosugars |
| AUPO937597A0 (en) * | 1997-09-24 | 1997-10-16 | Alchemia Pty Ltd | Protecting and linking groups for organic synthesis |
| AUPP823099A0 (en) | 1999-01-18 | 1999-02-11 | Alchemia Pty Ltd | Protecting groups for carbohydrate synthesis |
| US6476191B1 (en) * | 1999-02-05 | 2002-11-05 | Mixture Sciences, Inc. | Volatilizable solid phase supports for compound synthesis |
| US20010051349A1 (en) | 2000-02-17 | 2001-12-13 | Glycominds Ltd. | Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof |
| EP1175427B1 (en) | 1999-03-05 | 2010-08-18 | Massachusetts Institute Of Technology | Linkers for synthesis of oligosaccharides on solid supports |
| DE60110094T2 (en) * | 2000-08-18 | 2009-10-01 | Massachusetts Institute Of Technology, Cambridge | DEVICE AND METHOD FOR THE AUTOMATED SYNTHESIS OF OLIGOSACCHARIDES |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| AUPS143402A0 (en) * | 2002-03-28 | 2002-05-09 | Alchemia Pty Ltd | Anomeric derivatives of monosaccharides |
| US8603530B2 (en) * | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
| PT2121713E (en) | 2007-01-18 | 2013-06-25 | Genzyme Corp | Oligosaccharides comprising an aminooxy group and conjugates thereof |
| JP2011522805A (en) * | 2008-05-30 | 2011-08-04 | モメンタ ファーマシューティカルズ インコーポレイテッド | Sugar structures and methods of making and using such structures |
| DK3608330T3 (en) | 2008-12-16 | 2023-02-06 | Genzyme Corp | SYNTHETIC INTERMEDIATES FOR THE PREPARATION OF OLIGOSACCHARIDE-PROTEIN CONJUGATES |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1339748A (en) | 1970-07-02 | 1973-12-05 | Ici Ltd | Pyrimidine derivatives |
| US4062950A (en) | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
| JPS5829281B2 (en) | 1974-06-04 | 1983-06-22 | 日本曹達株式会社 | Barbiturate herbicide |
| PL103086B1 (en) | 1976-05-06 | 1979-05-31 | Ciba Geigy Ag | INSECTICIDE |
| DE2832698A1 (en) | 1978-07-26 | 1980-02-07 | Bayer Ag | SUBSTITUTED 5-PHENYLCARBAMOYL BARBITURIC ACIDS, PROCESS FOR THEIR PRODUCTION AND USE AS INSECTICIDES |
| US4283444A (en) | 1978-09-12 | 1981-08-11 | Ciba-Geigy Corporation | Method of protecting keratinous material from attack by insects that feed on keratin by treatment with 5-phenylcarbamoylbarbituric acid compounds |
| CH654720A5 (en) | 1981-09-03 | 1986-03-14 | Ciba Geigy Ag | STORAGE-RESISTANT MOTH PROTECTION FORMULAS. |
| CH658770A5 (en) | 1982-08-26 | 1986-12-15 | Ciba Geigy Ag | MUD AND COPPER PROTECTION AGENTS. |
| GB2145087B (en) | 1983-08-19 | 1987-02-04 | Ciba Geigy Ag | Barbituric acid derivatives |
| CH657015A5 (en) | 1984-06-27 | 1986-08-15 | Ciba Geigy Ag | MUD AND COPPER PROTECTION AGENTS. |
| GB2171099B (en) | 1985-02-15 | 1988-10-19 | Ciba Geigy Ag | 5-(azolyloxphenylcarbamoyl)barbituric acid derivatives as anthelmintics |
| US4753940A (en) | 1985-02-15 | 1988-06-28 | Ciba-Geigy Corporation | Barbituric acid derivatives |
| US4742128A (en) | 1985-10-15 | 1988-05-03 | Stamicarbon B.V. | Process for preparing a polymer alloy, molded product, and reaction injection molded products |
| US4797147A (en) | 1986-06-09 | 1989-01-10 | Stauffer Chemical Company | Herbicidal method and composition utilizing certain 5-(2-substituted benzoyl)-barbituric acids |
| US4938796A (en) | 1987-07-06 | 1990-07-03 | Ici Americas Inc. | Herbicidal compositions of acylated 1,3-dicarbonyl herbicides and antidotes therefor |
| DE3903404A1 (en) | 1989-02-06 | 1990-08-09 | Hoechst Ag | PYRIMID INTRION DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, CONTAINERS THEREOF AND THEIR USE AS A PEST CONTROL |
| US5959109A (en) | 1996-05-15 | 1999-09-28 | Neurocrine Biosciences, Inc. | Compounds and methods for increasing endogenous levels of corticotropin-releasing factor |
| AUPO190596A0 (en) * | 1996-08-26 | 1996-09-19 | Alchemia Pty Ltd | Oligosaccharide synthesis |
| AUPO536797A0 (en) * | 1997-02-28 | 1997-03-20 | Alchemia Pty Ltd | Protected aminosugars |
| CA2294259A1 (en) | 1997-06-21 | 1998-12-30 | Roche Diagnostics Gmbh | Barbituric acid derivatives with antimetastatic and antitumor activity |
| EP1017683A4 (en) | 1997-09-24 | 2002-03-06 | Alchemia Pty Ltd | Protecting and linking groups for organic synthesis |
| AUPP823099A0 (en) | 1999-01-18 | 1999-02-11 | Alchemia Pty Ltd | Protecting groups for carbohydrate synthesis |
-
1996
- 1996-08-26 AU AUPO1905A patent/AUPO190596A0/en not_active Abandoned
-
1997
- 1997-08-26 DE DE69716931T patent/DE69716931T2/en not_active Expired - Fee Related
- 1997-08-26 DK DK97935368T patent/DK0923528T3/en active
- 1997-08-26 JP JP10511091A patent/JP2001501174A/en active Pending
- 1997-08-26 DE DE0923528T patent/DE923528T1/en active Pending
- 1997-08-26 CN CN97199167A patent/CN1121375C/en not_active Expired - Fee Related
- 1997-08-26 HU HU0000069A patent/HUP0000069A3/en unknown
- 1997-08-26 EP EP97935368A patent/EP0923528B1/en not_active Expired - Lifetime
- 1997-08-26 WO PCT/AU1997/000544 patent/WO1998008799A1/en not_active Ceased
- 1997-08-26 ES ES97935368T patent/ES2150890T3/en not_active Expired - Lifetime
- 1997-08-26 AT AT97935368T patent/ATE227258T1/en not_active IP Right Cessation
- 1997-08-26 CA CA002264390A patent/CA2264390A1/en not_active Abandoned
- 1997-08-26 US US09/242,816 patent/US6573337B1/en not_active Expired - Fee Related
-
2002
- 2002-08-30 US US10/231,909 patent/US6723843B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2150890T3 (en) | 2003-07-01 |
| ATE227258T1 (en) | 2002-11-15 |
| AUPO190596A0 (en) | 1996-09-19 |
| HUP0000069A3 (en) | 2002-04-29 |
| EP0923528A1 (en) | 1999-06-23 |
| US6723843B2 (en) | 2004-04-20 |
| CN1121375C (en) | 2003-09-17 |
| DE923528T1 (en) | 2001-03-01 |
| EP0923528A4 (en) | 2000-07-19 |
| DK0923528T3 (en) | 2003-03-10 |
| ES2150890T1 (en) | 2000-12-16 |
| DE69716931D1 (en) | 2002-12-12 |
| DE69716931T2 (en) | 2003-07-31 |
| HUP0000069A2 (en) | 2000-05-28 |
| CN1234790A (en) | 1999-11-10 |
| CA2264390A1 (en) | 1998-03-05 |
| US20030027925A1 (en) | 2003-02-06 |
| JP2001501174A (en) | 2001-01-30 |
| US6573337B1 (en) | 2003-06-03 |
| WO1998008799A1 (en) | 1998-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0923528B1 (en) | Oligosaccharide synthesis | |
| Zhu et al. | A two‐directional approach for the solid‐phase synthesis of trisaccharide libraries | |
| Zhu et al. | A new set of orthogonal-protecting groups for oligosaccharide synthesis on a polymeric support | |
| WO1984001777A1 (en) | Method for carrying out the organic synthesis of oligosaccharides containing galactosamine-uronic acid patterns, new oligosaccharides obtained and biological applications thereof | |
| US6462183B1 (en) | Protected aminosugars | |
| CN114874345A (en) | Chemical synthesis method of helicobacter pylori core lipopolysaccharide oligosaccharide antigen sugar chain | |
| Hogendorf et al. | Light fluorous synthesis of glucosylated glycerol teichoic acids | |
| Iyer et al. | Design and synthesis of hyaluronan-mimetic gemini disaccharides | |
| Chmielewski et al. | Reverse anomeric effect of the carbamoyl group of 2, 6-anhydroheptonamides | |
| Weigelt et al. | A linker for solid phase carbohydrate synthesis, permitting the introduction of variable anomeric functionality in the release step | |
| AU728149B2 (en) | Oligosaccharide synthesis | |
| JP4852689B2 (en) | Selective oxidation process of oligosaccharide primary alcohol | |
| US4935503A (en) | Azidochlorination and diazidization of glycals | |
| JP2003527397A (en) | Method for producing perbenzylated 1-o-glycoside | |
| Wessel et al. | Selectively Deoxygenated Derivatives of β-Maltosyl-(1→ 4)-Trehalose as Biological Probes | |
| US6545135B2 (en) | Process for the production of perbenzylated 1-O-glycosides | |
| US5837862A (en) | Sialyl Lewis X mimetics incorporating mannopeptides | |
| US6831164B2 (en) | Process for the production of peracylated 1-0-glycosides | |
| Whitfield et al. | Syntheses of Model Oligosaccharides of Biological Significance. VI. Glycosylation at C-3 of Galactose: A Synthesis of Trideuterio-Methyl 3-O-(-Acetamido-2-Deoxy-β-D-Glucopyranosyl)-β-D-Galactopyranoside | |
| AU730910B2 (en) | Protected aminosugars | |
| JP3101710B2 (en) | Sulfated oligosaccharide compounds | |
| JP3163358B2 (en) | Sulfated oligosaccharide compounds | |
| US6908989B2 (en) | Process for the production of perbenzylated 1-O-glycosides | |
| GB2071658A (en) | Synthesis of daunosamine hydrochloride and intermediates used in its preparation | |
| JP2704862B2 (en) | Tin derivatives at the anomeric position of sugars |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990310 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20000606 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07C 59/353 A, 7C 07C 59/90 B, 7C 07C 69/716 B, 7C 07C 69/738 B, 7C 07C 229/32 B, 7C 07C 257/06 B, 7C 07H 5/06 B, 7C 08J 7/14 B, 7C 08J 7/16 B, 7C 07H 15/18 B |
|
| EL | Fr: translation of claims filed | ||
| TCAT | At: translation of patent claims filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: BA2A Ref document number: 2150890 Country of ref document: ES Kind code of ref document: T1 |
|
| DET | De: translation of patent claims | ||
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| 17Q | First examination report despatched |
Effective date: 20011128 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20021106 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20021106 |
|
| REF | Corresponds to: |
Ref document number: 227258 Country of ref document: AT Date of ref document: 20021115 Kind code of ref document: T |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 69716931 Country of ref document: DE Date of ref document: 20021212 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030206 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KELLER & PARTNER PATENTANWAELTE AG |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2150890 Country of ref document: ES Kind code of ref document: T3 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030831 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20030807 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: CA |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20080613 Year of fee payment: 12 Ref country code: CH Payment date: 20080605 Year of fee payment: 12 Ref country code: LU Payment date: 20080611 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20080618 Year of fee payment: 12 Ref country code: NL Payment date: 20080606 Year of fee payment: 12 Ref country code: IE Payment date: 20080617 Year of fee payment: 12 Ref country code: ES Payment date: 20080922 Year of fee payment: 12 Ref country code: DE Payment date: 20080606 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20080828 Year of fee payment: 12 Ref country code: FR Payment date: 20080606 Year of fee payment: 12 Ref country code: AT Payment date: 20080606 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080617 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20090119 Year of fee payment: 12 |
|
| BERE | Be: lapsed |
Owner name: *ALCHEMIA PTY. LTD Effective date: 20090831 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20100301 Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090826 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100430 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090826 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100301 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090826 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100302 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20090827 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090826 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090826 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090826 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090827 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090827 |







